A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of
A phase 3 trial of Cetuximab sarotalocan, Pembrolizumab, Carboplatin in head and neck squamous cell carcinoma, run by Rakuten Medical, Inc., now recruiting.
Overview
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases is a phase 3 interventional study registered as NCT06699212 by Rakuten Medical, Inc., with 412 participants planned, started 2024-12-24 and due to reach its primary completion in 2028-09. Interventions recorded: ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin, Cisplatin, 5-fluorouracil. Conditions listed: Recurrent Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan
Shares Docetaxel, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
- TrialASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
Shares Rakuten Medical, Head and neck squamous cell carcinoma.
- TrialAn Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Shares Rakuten Medical, Head and neck squamous cell carcinoma, Pembrolizumab.
- TrialStudy of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Shares Docetaxel, Cisplatin, Carboplatin, Pembrolizumab.
- TrialStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Shares Docetaxel, Cisplatin, Carboplatin, Pembrolizumab.
- TrialA Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Shares Cisplatin, Carboplatin, Head and neck squamous cell carcinoma, Pembrolizumab.
- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin, Pembrolizumab.
- TrialGEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Shares Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin, Head and neck squamous cell carcinoma.